signal transduction; hypertrophy; cardiac THE LOW-MOLECULAR-WEIGHT GTPase Rho is a wellestablished regulator of actin cytoskeletal organization in fibroblasts (25, 30) . In addition, a role for Rho in regulating c-fos gene expression has been reported (5, 7, 9, 41) . The effects of Rho on c-fos gene expression in NIH 3T3 cells are mediated through the c-fos serum response element (SRE) and occur in a ternary complex factor (TCF)-independent manner.
Among the multitude of putative Rho effectors that have been cloned are a number of protein kinases that bind to and are activated by Rho (reviewed in Ref. 42 ).
Rho kinase (ROK), which is the most extensively characterized Rho effector, was shown to regulate Rhodependent cytoskeletal rearrangement. Transcriptional activation of the c-fos SRE by Rho was originally suggested to be mediated through ROK, but several lines of evidence from recent studies using a pharmacological ROK inhibitor Y-27632 and Rho effector mutants argue against ROK involvement in SRE-dependent transcription (5, 8, 13, 14, 19, 20, 32, 33) . Other less well-characterized protein kinases that are activated by Rho are protein kinase N (PKN), also called protein kinase C-related kinase 1 (PRK1) (2, 46) , and its closely related family member PRK2 (44) . PKN and PRK2 share significant homology to PKC family members in their catalytic domains, but their amino terminal regulatory domains are distinct (22, 26) . PKN is ubiquitously expressed in human tissues (23) and has been shown to interact with cytoskeletal proteins (24) and to increase glucose transport in adipocytes (37). A role for PKN in cytoskeletal or transcriptional regulation has not been clearly documented.
Rho has been implicated as a mediator of hypertrophic signaling in neonatal rat ventricular myocytes (3, 10, 12, 31, 38) . In this well-characterized cultured cell model of hypertrophy, G q -coupled receptor agonists stimulate the expression of c-fos and other immediate early genes, promote reexpression of embryonic genes, including atrial natriuretic factor (ANF), and upregulate embryonic isoforms of contractile protein genes such as myosin light chain (MLC)-2v (4). We have shown that Rho is required for increases in ANF and MLC-2 expression mediated by ␣ 1 -adrenergic receptor stimulation and that activated Rho can induce myofilament organization and increase myocyte size (12, 31) . Rho function is also necessary for angiotensin IIstimulated myofibrillar changes and ANF induction (3) as well as G␣ q -regulated ANF gene expression (10, 31) . Activated Rho was also recently shown to stimulate transcriptional activation of the TCF-independent c-fos SRE in cardiomyocytes (41) .
The ANF promoter contains two SRE-like cis elements that appear to function in a TCF-independent fashion (36), since they do not contain the flanking Ets motifs responsible for TCF binding. These SRE-like elements, along with Sp-1 sites, are required for conferring maximal ␣ 1 -adrenergic receptor-stimulated ANF reporter gene expression (36) . The experiments pre-sented here tested the hypothesis that Rho regulates ANF expression through the ANF SRE. In addition we examined the ability of putative Rho effectors, ROK, PRK1, and PKN, to transcriptionally activate ANF reporter gene expression and determined whether regulation occurred at the level of the SRE.
EXPERIMENTAL PROCEDURES
Plasmids and reporter constructs. Five reporter genes in which the 5Ј-flanking sequence of the rat ANF promoter or SRE consensus sequences were fused to firefly luciferase cDNA were used in this study: ANF-638, ANF-134, ANF134c114, 3xANF SRE, and 3xc-fos SRE. The 638-bp promoter (ANF-638) includes the 5Ј-flanking sequence from ANF Ϫ638 to ϩ65 fused to luciferase, whereas the 134-bp promoter (ANF-134) includes ANF Ϫ134 to ϩ65. Truncation of ANF-638 has been shown to confer maximal stimulation compared with the full-length promoter (36) . The ANF-134 contains one SRE from ANF Ϫ117 to Ϫ108 with the sequence CTTTAAAAGG. This promoter was mutated at the SRE to C TTGCCCCTG (mutations underlined), rendering the SRE nonfunctional (ANF134c114). In addition, three ANF SRE sequences, ACTGATAACTTTAAAAGGGCATCT, or three c-fos SRE sequences, CAGGATGTCCATATTAGGACATCT (SREs underlined), linked in tandem behind a minimal ANF promoter consisting of ANF Ϫ65 to ϩ65 (ANF 65) and fused to luciferase cDNA were utilized (39) . Importantly, it should be noted that the three c-fos SRE sequences include a TCFbinding (Ets) domain (Ets motif in bold) flanking the SRE, whereas the three ANF SRE sequences, previously shown to act in a TCF-independent manner, lack a flanking Ets motif.
Other constructs tested here were obtained from the following sources. Dominant negative Rho (N19Rho) was provided by Dr. Gary Bokoch (The Scripps Research Institute). Constitutively activated PKN and Rho kinase plasmids were provided by Drs. Yoshitaka Ono (Kobe University) and Kozo Kaibuchi (Nara Institute of Science and Technology, Japan), and constitutively activated PRK2 was provided by Dr. Jeffrey Settleman (Massachusetts General Hospital Cancer Center and Harvard Medical School). All constitutively activated mutants of these proteins had deletions of their regulatory domains, leaving their catalytic domains intact.
Cell culture. Neonatal rat ventricular myocytes (NRVM) were prepared from 2-to 3-day-old Sprague-Dawley rat pups as described previously (15, 35) . The ventricles were collagenase digested and myocytes purified over a Percoll gradient. The cells were plated on six-well plates coated with 1% gelatin and cultured overnight in a 4:1 mixture of Dulbecco's modified Eagle's medium and medium 199, supplemented with 10% horse serum, 5% fetal calf serum, 100 U/ml penicillin, and 100 µg/ml streptomycin.
Transient transfections. Transfection of NRVM was carried out using a modified calcium phosphate method as previously described (35) . Briefly, six-well plates with each well containing 3 ml of serum-containing media were transfected with a total of 6.6 µg of plasmid DNA (4.8 µg of cDNA and 1.8 µg of luciferase reporter plasmid). After transfection, cells were washed and maintained for 48 h in serum-free media with or without ␣ 1 -adrenergic receptor agonist PE (100 µM ϩ 2 µM propranolol to block ␤-adrenergic receptors). Reporter gene activity was determined by lysing cells in buffer containing 1% Triton X-100, and luciferase activity was quantified using a Berthold luminometer as described (28) . Luciferase data were normalized to protein concentration determined by Bradford analysis. The data were not normalized to ␤-galactosidase (␤-Gal), because we have found that most agonists and kinases, including PE and activated PKN (PKN*) activate the cytomegalovirus (CMV) or SV40 promoters, which drive the ␤-Gal constructs; thus ␤-Gal activity does not reflect transfection efficiency. Although ␤-Gal was not routinely used, the relative responses to stimuli or of various promoters tested here were the same when normalized to protein as when normalized to ␤-Gal in the assays where it was used. Each experiment was performed in triplicate, and the data in the figures represent a minimum of three experiments. Data were normalized to the maximal response (established using 100 µM PE) to pool separate experiments.
RESULTS
Activated PKN and PRK2 but not Rho kinase stimulate ANF gene expression. Constitutively activated forms of putative Rho effectors were transiently expressed in NRVM, and their effects on ANF-luciferase gene expression were examined. A Rho kinase mutant, made constitutively active by removal of the NH 2 -terminal regulatory domain, did not stimulate ANF-638-luciferase reporter gene expression in NRVM (Fig. 1) . Constitutively active forms of the protein kinase C-related kinases PRK2 and PKN (also known as PRK1), generated by the removal of their respective regulatory domains, were also examined for their ability to stimulate ANF-638-luciferase expression. Activated PKN gave a robust stimulation equivalent to ϳ60% of that induced by the well-established hypertrophic agonist PE (P Ͻ 0.01). The stimulation by PRK2 was significant (P Ͻ 0.01) but modest compared with that seen with PKN ( Fig. 1) .
Rho-mediated ANF expression requires a functional SRE. Because Rho effects on c-fos gene expression are mediated via the SRE, we examined the requirement for the SRE in Rho-and PKN-mediated transcriptional activation of the ANF gene. For these studies we tested both the ANF-638 promoter, which contains two SRE sites, as well as the truncated ANF-134 promoter, which contains only one SRE-like sequence. We also utilized the same promoters in which the SRE was mutated to render it nonfunctional (ANF638c114 and Fig. 1 . Activated protein kinase N (PKN) and protein kinase Crelated kinase 2 (PRK2) but not Rho kinase (ROK) stimulate atrial natriuretic factor (ANF) gene expression. Myocytes were transfected with ANF-638 luciferase reporter gene and appropriate empty vector or constitutively activated kinase (ROK*, PRK2*, PKN*) and incubated in the presence or absence of 100 µM phenylephrine (PE). PE response was designated as 100%, and data in each experiment were normalized to their respective PE responses. Each bar represents mean Ϯ SE from at least 3 experiments performed in triplicate. *P Ͻ 0.01 compared with vector. ANF134c114). These constructs have been used previously to demonstrate the dependence of PE-stimulated ANF expression on these proximal SREs (36, 39) . A dominant negative form of Rho was tested for its ability to block responses to PE. The data shown in Fig. 2 are expressed as a percentage of the response to PE to facilitate pooling of experiments in which the absolute effect of PE varied. For ANF-638, N19Rho inhibited the response to PE by ϳ70%; the response on ANF-134 to PE was inhibited by ϳ60% ( Fig. 2A) . In contrast N19Rho did not significantly inhibit PE activation of the ANF134c114 or ANF638c114 promoters lacking a SRE (Fig. 2B) .
A functional SRE is needed for transcriptional activation mediated by PKN. The involvement of the proximal cis SRE element in transcriptional activation of the ANF gene by PKN was also examined. As shown in Fig.  3 , the ANF-134 promoter retains responsiveness to PKN. However, when the proximal SRE site in either the ANF-638 or ANF-134 promoters is mutated to render it nonfunctional, the stimulation by activated PKN is markedly inhibited (ANF638c114) or lost (ANF134c114). These data demonstrate the requirement for the SRE in transcriptional activation of the ANF promoter by PKN (Fig. 3) . Because the mutation of the SRE in ANF-638 did not fully prevent the response to PKN, we examined the involvement of the Sp-1 site, which, like the SRE, has been shown to be important in PE-mediated ANF stimulation (36) . Mutation of the Sp-1 site at Ϫ69 in the ANF-638 reporter gene (ANF638c69) resulted in a ϳ55% loss in stimulation by PKN, demonstrating that the Sp-1 site is also involved in transcriptional activation of ANF by PKN.
Rho and PKN regulate transcriptional activation of ANF SRE and c-fos SRE.
To obtain further evidence that the SRE derived from the ANF gene could mediate the Rho-dependent effects of PE and the response to PKN, we used reporter gene constructs in which three copies of the SRE derived from the ANF promoter (3xANF SRE) were linked in tandem behind an ANF minimal promoter. Constructs containing three copies of the SRE from the c-fos promoter were also examined (39) . PE induced a robust activation of the 3xANF SRE as well as the 3xc-fos SRE reporter genes. Significant (Ͼ40%) inhibition of both PE-stimulated ANF and c-fos expression was achieved by coexpression of N19Rho (Fig. 4A) . PKN also stimulated the 3xANF SRE and 3xc-fos SRE luciferase. Interestingly, the fold stimulation of 3xANF SRE by PKN was ϳ80% of that induced by PE (Fig. 4B) , whereas the stimulatory effect of PKN on 3xc-fos SRE luciferase expression was modest compared with that of PE (Fig. 4B ).
DISCUSSION
The low-molecular-weight GTPase Rho has been shown to regulate diverse cellular functions. First identified as a regulator of actin stress fiber and focal adhesion complex formation (30) , it has since been implicated in modulating gene expression, mitogenactivated protein (MAP) kinase activation, cell cycle progression, transformation, and smooth muscle contraction (9, 29, 33, 43) . A role for Rho in myofibrillar organization and gene expression associated with myocardial cell hypertrophy has been demonstrated by our lab and others (3, 10, 12, 19, 31, 38, 41, 45) . ANF-638, ANF-134; B: ANF638c114, ANF134c114) and empty vector or dominant negative Rho (N19Rho) and incubated in the absence or presence of 100 µM PE. PE response was designated as 100%, and data in each experiment were normalized to the respective PE response. Absolute fold stimulation by PE (over vector control) was as follows: 62-fold for ANF-638; 21-fold for ANF638c114; 7-fold for ANF-134; and 3-fold for ANF134c114. Each bar represents mean Ϯ SE of data from at least 3 experiments performed in triplicate. #P Ͻ 0.01 compared with vector ϩ PE. Over the past few years numerous Rho effectors have been isolated and cloned. Currently, a question of great interest is how these effectors carry out the various and diverse functions of Rho. The best characterized of these effectors is Rho kinase, which has been convincingly shown to regulate cytoskeletal rearrangement (1, 5, 14, 20) and smooth muscle contraction (16-18, 34, 40, 43) . We showed that three distinct Rho kinase mutants were able to attenuate Rho-stimulated myofibrillar organization and ANF expression in cardiomyocytes (12) . Notably, responses to activated Rho and PE were most fully abolished by an interfering mutant consisting of the Rho-binding domain, which could also inhibit interactions of Rho with other effectors. Thus it was suggested that Rho signals through other effectors in addition to Rho kinase to elicit these hypertrophic responses.
To further examine the involvement of other Rho effectors, we compared the ability of three Rhoregulated kinases to stimulate ANF expression. The finding that constitutively activated Rho kinase failed to stimulate ANF reporter gene expression was surprising because the same constitutively activated mutant was previously reported to cause transcriptional activation of the c-fos SRE in fibroblasts (5) . Rho kinase regulation of the c-fos SRE may be cell-type specific because Rho was found to regulate MAP kinase activation in some cell types (29) but not others (6, 21) , including cardiac myocytes (31) . Recent reports using Rho effector mutants and Y-27632, a Rho kinase inhibitor, are consistent with our data and argue against a role for Rho kinase in SRE-mediated transcriptional regulation (32, 33) . However, we recently found that a selective dominant negative ROK mutant is able to block PE-induced stimulation of the ANF-638 (M. R. Morissette, unpublished observations). (32) . Endothelin-1 (ET-1)-mediated ANF gene expression in cardiomyocytes was also recently shown to be Rho kinasedependent based on the use of the pharmacological inhibitor compound, Y-27632. Notably the responses to ET-1 and Rho kinase were independent of the SRE (19) , thus Rho kinase may play a role in mediating PE and ET-1-induced ANF transcription through response elements other than the SRE.
The PKC-related kinases PKN and PRK2 were also examined. Previously published data indicated that PRK2 can act in concert with Rho to potentiate the effects of Rho on SRE transcriptional activation (27) . In NRVM, both PKN and PRK2 stimulated ANF luciferase gene expression above vector control; however, PKN was significantly more efficacious in this regard (Fig. 1) . This same stimulation pattern was seen using the ANF-134, 3xANF SRE, and 3xc-fos SRE in addition to the ANF-638 (data not shown). We cannot rule out the possibility that this selectivity is the result of differences in expression levels of the two protein kinases, because attempts to assess expression levels are compromised by the low transfection efficiency of the NRVMs. Nonetheless, it is clear that expression of activated PKN can induce ANF luciferase gene expression.
That the stimulatory effect of PE on the ANF-134 promoter is attenuated but not fully abolished by disruption of the SRE site suggested that additional elements in the 134-bp fragment (e.g., Sp-1) sites are responsive to PE (36) . Studies using ANF-638 indicate that mutation of the proximal SRE results in incomplete inhibition of the response to PKN and that mutation of the Sp-1 site also reduces PKN stimulation (Fig. 3) . These data support the notion that similar to previously published data using PE, the control of ANF transcription by PKN may utilize Sp-1 as well as SRE sites.
Rho has been shown to activate the c-fos SRE via SRF in a TCF-independent manner (9, 41). The ANF SRE has also been hypothesized to be activated by SRF independent of TCF (36). Interestingly, whereas PKN robustly activated 3xANF SRE-driven luciferase expression, PKN was a relatively modest activator of 3xc-fos SRE relative to PE. The reason for this apparent selectivity of PKN for the ANF versus the c-fos SRE is unknown but may result from the lack of an Ets motif adjacent to the ANF SRE. Because TCF apparently does not bind to this region of the ANF gene (36, 39) PKN may be a more effective activator of SREmediated gene expression in its absence. Additionally, there is a slight difference in the core sequences of the ANF and c-fos SREs; in the c-fos gene the SRE is a consensus match (CC[A/T]6GG), whereas in the ANF gene the SRE has one mismatch. This mismatch, which is known to slightly reduce the affinity of the SRE for SRF (11) , could also contribute to the preferential stimulation of the ANF SRE by PKN.
The data in this paper suggest that transcriptional regulation of the ANF gene by Rho and one of its effectors PKN occurs at the level of the SRE. Thus Rho and PKN appear to share a distal end point in ANF gene regulation. Experiments using a putative dominant negative form of PKN (data not shown) have not provided evidence that this enzyme is a direct mediator of the physiological response to PE or Rho. Multiple kinase pathways, including PKC, MAP kinases, and calcium/calmodulin kinase, have been implicated in the regulation of the ANF promoter. Thus it is not surprising that dominant negative Rho or PKN does not fully inhibit PE-stimulated ANF luciferase expression and that other signaling molecules besides Rho are involved in transducing PE-evoked signals to the SRE. Nonetheless we establish for the first time that the Rho effector PKN modulates cardiac gene expression and demonstrate that PKN has a striking effect on SRE-mediated ANF gene expression in cardiac myocytes.
